Enadoline is a drug which acts as a highly selective κ-opioid agonist.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H32N2O3 |
Molar mass | 396.531 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
In human studies, it produced visual distortions and feelings of dissociation, reminiscent of the effects of salvinorin A.[1]
It was studied as a potential analgesic, but abandoned because of the dose-limiting effects of dysphoria, which could be expected from a κ-opioid agonist. There was mention of its potential in treating comatose head injury or stroke victims, where that type of side effect would be immaterial.[2]
Potency
editWhen enadoline was first reported in 1990, it was "the most potent κ-selective analgesic ever reported ... 25 times more potent than morphine and 17 times more potent than U-62066".[3]
See also
editReferences
edit- ^ Walsh SL, Strain EC, Abreu ME, Bigelow GE (September 2001). "Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans". Psychopharmacology. 157 (2): 151–162. doi:10.1007/s002130100788. PMID 11594439. S2CID 10507758.
- ^ Barber A, Gottschlich R (October 1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opinion on Investigational Drugs. 6 (10): 1351–1368. doi:10.1517/13543784.6.10.1351. PMID 15989506.
- ^ Halfpenny PR, Horwell DC, Hughes J, Hunter JC, Rees DC (January 1990). "Highly selective kappa-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted-cyclohexyl]arylacetamide derivatives". Journal of Medicinal Chemistry. 33 (1): 286–291. doi:10.1021/jm00163a047. PMID 2153208.